Tarsus Pharmaceuticals, Inc. Common Stock (TARS) Financials

Key financial figures for Tarsus Pharmaceuticals, Inc. Common Stock (Q2 2026).

Revenue

$174M

Net Income

-$19M

EPS

$-0.43

Total Assets

$611M

Operating Cash Flow

$61M

Full income statement, balance sheet, and cash flow for Tarsus Pharmaceuticals, Inc. Common Stock on SentiSense.